Toca 511 and Toca Fc will be evaluated for recurrent glioblastoma or anaplastic astrocytoma in a registrational study, Toca 5, later this year. Interim data from two ongoing clinical trials have shown extended survival compared to historical benchmarks, encouraging dose response effect and durable tumor shrinkage. A study evaluating Toca 511 and Toca FC for additional cancer indications is also planned for 2016.
Toca 511 is a retroviral replicating vector (RRV) which delivers a gene for the enzyme cytosine deaminase (CD) to the cancer cells. Toca FC is an oral antifungal that is converted to 5-fluorouracil (5-FU) that selectively kills infected cancer cells. Immune activation locally in the tumor occurs through a combination of mechanisms which leads to breaking of immune tolerance and activation of the immune system selectively against the cancer cells.
For more information call (858) 412-8400 or visit Tocagen.com.